Johnson & Johnson $JNJ Stake Increased by M Holdings Securities Inc.

Key Points

• M Holdings Securities Inc. increased its stake in Johnson & Johnson by 15.1% in Q1, now owning 19,506 shares valued at approximately $3.24 million.
• Johnson & Johnson reported earnings of $2.77 EPS for the last quarter, surpassing analyst estimates of $2.68, and had a revenue of $23.74 billion, up 5.8% year-over-year.
• The company declared a quarterly dividend of $1.30 per share, with a dividend yield of 2.9% and a payout ratio of 55.61%.

M Holdings Securities Inc. raised its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 15.1% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 19,506 shares of the company's stock after purchasing an additional 2,558 shares during the period. M Holdings Securities Inc.'s holdings in Johnson & Johnson were worth $3,235,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in the business. Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter worth about $47,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson in the 1st quarter valued at about $49,000. Capital A Wealth Management LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at about $50,000. Finally, Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the 1st quarter valued at about $52,000. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Up 1.2%

NYSE:JNJ opened at $176.76 on Monday. The stock's 50 day moving average price is $161.28 and its 200 day moving average price is $158.43. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $177.27. The company has a market capitalization of $425.70 billion, a P/E ratio of 18.90, a P/E/G ratio of 2.25 and a beta of 0.41. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the company posted $2.82 earnings per share. The firm's revenue was up 5.8% on a year-over-year basis. On average, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on JNJ shares. Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Erste Group Bank raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Finally, Leerink Partnrs lowered shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.